Company intelligence / Profile preview

Mirrx Therapeutics

Vejle, Denmark

Ownership: Private
Development stage: Other

Overview

Mirrx Therapeutics developed the Blockmir technology platform, which uses antisense oligonucleotides to block specific microRNA:mRNA interactions. The company achieved seed financing in 2010 to advance in vivo proof of concept for the technology. After a legal dispute resolved in 2015, the company has restarted operations.[2][4]

Therapeutic areas: OncologyImmunologyInfectious DiseasesMetabolic Disorders
Modalities: Antisense oligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on Mirrx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirrx Therapeutics.

Explore the full profile